BACKGROUND: Diminished dopaminergic neurotransmission contributes to decreased reward and negative eating behaviors in obesity. Bariatric surgery is the most effective therapy for obesity and rapidly reduces hunger and improves satiety through unknown mechanisms. We hypothesized that dopaminergic neurotransmission would be enhanced after Roux-en-Y-Gastric Bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) surgery and that these changes would influence eating behaviors and contribute to the positive outcomes from bariatric surgery. METHODS: Five females with obesity were studied preoperatively and at approximately 7 weeks after RYGB or VSG surgery. Subjects underwent positron emission tomography (PET) imaging with a dopamine type 2 (DA D2) receptor radioligand whose binding is sensitive to competition with endogenous dopamine. Regions of interest (ROI) relevant to eating behaviors were delineated. Fasting enteroendocrine hormones were quantified at each time point. RESULTS: Body weight decreased as expected after surgery. DA D2 receptor availability decreased after surgery. Regional decreases (mean+/-SEM) were caudate 10+/-3%, putamen 9+/-4%, ventral striatum 8+/-4%, hypothalamus 9+/-3%, substantia nigra 10+/-2%, medial thalamus 8+/-2%, and amygdala 9+/-3%. These were accompanied by significant decreases in plasma insulin (62%) and leptin (41%). CONCLUSION: The decreases in DA D2 receptor availability after RYGB and VSG most likely reflect increases in extracellular dopamine levels. Enhanced dopaminergic neurotransmission may contribute to improved eating behavior (e.g. reduced hunger and improved satiety) following these bariatric procedures. 2010 Elsevier B.V. All rights reserved.
BACKGROUND: Diminished dopaminergic neurotransmission contributes to decreased reward and negative eating behaviors in obesity. Bariatric surgery is the most effective therapy for obesity and rapidly reduces hunger and improves satiety through unknown mechanisms. We hypothesized that dopaminergic neurotransmission would be enhanced after Roux-en-Y-Gastric Bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) surgery and that these changes would influence eating behaviors and contribute to the positive outcomes from bariatric surgery. METHODS: Five females with obesity were studied preoperatively and at approximately 7 weeks after RYGB or VSG surgery. Subjects underwent positron emission tomography (PET) imaging with a dopamine type 2 (DA D2) receptor radioligand whose binding is sensitive to competition with endogenous dopamine. Regions of interest (ROI) relevant to eating behaviors were delineated. Fasting enteroendocrine hormones were quantified at each time point. RESULTS: Body weight decreased as expected after surgery. DA D2 receptor availability decreased after surgery. Regional decreases (mean+/-SEM) were caudate 10+/-3%, putamen 9+/-4%, ventral striatum 8+/-4%, hypothalamus 9+/-3%, substantia nigra 10+/-2%, medial thalamus 8+/-2%, and amygdala 9+/-3%. These were accompanied by significant decreases in plasma insulin (62%) and leptin (41%). CONCLUSION: The decreases in DA D2 receptor availability after RYGB and VSG most likely reflect increases in extracellular dopamine levels. Enhanced dopaminergic neurotransmission may contribute to improved eating behavior (e.g. reduced hunger and improved satiety) following these bariatric procedures. 2010 Elsevier B.V. All rights reserved.
Authors: Kimberley E Steele; Gregory P Prokopowicz; Michael A Schweitzer; Thomas H Magunsuon; Anne O Lidor; Hiroto Kuwabawa; Anil Kumar; James Brasic; Dean F Wong Journal: Obes Surg Date: 2009-10-29 Impact factor: 4.129
Authors: Ralph Peterli; Bettina Wölnerhanssen; Thomas Peters; Noémie Devaux; Beatrice Kern; Caroline Christoffel-Courtin; Juergen Drewe; Markus von Flüe; Christoph Beglinger Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: Patrizia Riccardi; Ron Baldwin; Ronald Salomon; Sharlet Anderson; Mohammad S Ansari; Rui Li; Benoit Dawant; Amy Bauernfeind; Dennis Schmidt; Robert Kessler Journal: Biol Psychiatry Date: 2007-06-27 Impact factor: 13.382
Authors: Jussi Hirvonen; Hasse Karlsson; Jaana Kajander; Juha Markkula; Helena Rasi-Hakala; Kjell Någren; Jouko K Salminen; Jarmo Hietala Journal: Psychopharmacology (Berl) Date: 2008-02-05 Impact factor: 4.530
Authors: Lars Sjöström; Kristina Narbro; C David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Ted Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Göran Agren; Lena M S Carlsson Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: Kelly P Cosgrove; Maria G Veldhuizen; Christine M Sandiego; Evan D Morris; Dana M Small Journal: Synapse Date: 2015-03-11 Impact factor: 2.562
Authors: Mike J F Robinson; Paul R Burghardt; Christa M Patterson; Cameron W Nobile; Huda Akil; Stanley J Watson; Kent C Berridge; Carrie R Ferrario Journal: Neuropsychopharmacology Date: 2015-03-12 Impact factor: 7.853
Authors: S Frank; B Wilms; R Veit; B Ernst; M Thurnheer; S Kullmann; A Fritsche; N Birbaumer; H Preissl; B Schultes Journal: Int J Obes (Lond) Date: 2013-04-29 Impact factor: 5.095